Abstract: Conventional ways of reducing pressure in the eye have inherent drawbacks and one such way to reduce these drawbacks is to provide an ocular drainage implant including a pliable plate which is so sized and shaped as to enable it to be positioned on a sclera surface or a sub-scleral space of an eye comprising a first exterior face and a second exterior face, with a plurality of apertures extending between the first and second faces, and a fluid drainage tube retaining structure; and a valve-less fluid drainage tube connected to the retaining structure and providing the implant with a longitudinal axis, the valve-less fluid drainage tube being adapted to drain fluid from an anterior chamber of the eye to the subconjunctival or the suprachoroidal space, wherein the retaining structure extends substantially across an entire dimension of the plate.

Abstract: Conventional ways of reducing pressure in the eye have inherent drawbacks and one such way to reduce these drawbacks is to provide an ocular drainage implant including a pliable plate which is so sized and shaped as to enable it to be positioned on a sclera surface or a sub-scleral space of an eye comprising a first exterior face and a second exterior face, with a plurality of apertures extending between the first and second faces, and a fluid drainage tube retaining structure; and a valve-less fluid drainage tube connected to the retaining structure and providing the implant with a longitudinal axis, the valve-less fluid drainage tube being adapted to drain fluid from an anterior chamber of the eye to the subconjunctival or the suprachoroidal space, wherein the retaining structure extends substantially across an entire dimension of the plate.

Abstract: The present invention relates to the use of dronedarone or a pharmaceutically acceptable salt thereof for the preparation of a drug for the prevention of atrial fibrillation wherein said use comprises the following precaution of use steps: a) initiating dronedarone administration in patients with atrial fibrillation or atrial flutter, b) performing electrocardiograms serially.

Abstract: The invention relates to the use of idrabiotaparinux for the treatment and secondary prevention of thrombotic pathologies, wherein the use of idrabiotaparinux involves a decrease in the incidence of bleedings, in particular major bleedings, during said treatment.